Debates in allergy medicine: Molecular allergy diagnosis with ISAC will replace screenings by skin prick test in the future

In today’s clinical practice patients’ skin is used as screening organ for diagnosing type 1 allergy. According to European guidelines skin prick testing with a panel of 18 allergen extracts is recommended, in the US between 10 to 50 allergens are used. The specificity and sensitivity of skin testin...

Full description

Saved in:
Bibliographic Details
Published in:The World Allergy Organization journal Vol. 10; no. 1; p. 33
Main Authors: Jensen-Jarolim, E., Jensen, A.N., Canonica, G.W.
Format: Journal Article
Language:English
Published: London Elsevier Inc 19.09.2017
BioMed Central
BioMed Central Ltd
Elsevier BV
Elsevier
Subjects:
Allergens
Allergies
Allergology
Allergy
Allergy tests
Asthma
Biological markers
Debate
Debates in Allergy Medicine
Diagnosis
Food allergies
Health aspects
Immunology
Immunotherapy
Medical diagnosis
Medicine
Medicine & Public Health
Patients
Skin
Allergen Extracts
Allergy Diagnosis
Molecular Allergy
Skin Prick Test (SPT)
Immuno Solid-phase Allergen Chip (ISAC)
ISSN:1939-4551, 1939-4551
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In today’s clinical practice patients’ skin is used as screening organ for diagnosing type 1 allergy. According to European guidelines skin prick testing with a panel of 18 allergen extracts is recommended, in the US between 10 to 50 allergens are used. The specificity and sensitivity of skin testing is individually highly variable depending on age, body mass, and skin barrier status. In atopic inflammation skin testing gives more false positive results. Smaller skin area and strain limits prick testing in small children. Although the risk for systemic reactions in skin prick testing is very small, emergency medications must be available. Considering the fact that IgE is the only reliable biomarker for type I allergy, upfront IgE screening with ISAC, followed by fewer skin tests to approve positive sensitizations, is proposed. It is time to arrive in the age of molecular allergy diagnosis in daily patient care.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1939-4551
1939-4551
DOI:10.1186/s40413-017-0162-3